Vimarsana
Biggest News Aggregation in the World

Page 2 - Mark Lebwohl News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Mark Lebwohl. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Mark Lebwohl Today - Breaking & Trending Today

FDA Approves Bimekizumab for Moderate-To-Severe Plaque Psoriasis - Vimarsana News

FDA Approves Bimekizumab for Moderate-To-Severe Plaque Psoriasis

Bimekizumab is a novel, humanized monoclonal IgG1 antibody that potently and selectively neutralizes both IL-7A and IL-17F, which are key cytokines driving inflammatory processes in plaque psoriasis.

FDA Approves Bimekizumab for Adults with Plaque Psoriasis - Vimarsana News

FDA Approves Bimekizumab for Adults with Plaque Psoriasis

The approval for the IL-17A and IL-17F inhibitor is supported by data showing about 80% of patients achieved nearly clear skin within 4 doses.

FDA Approves Bimekizumab for Plaque Psoriasis in Adults - Vimarsana News

FDA Approves Bimekizumab for Plaque Psoriasis in Adults

Bimekizumab is the first IL-17A and IL-17F inhibitor approved by the FDA for adults with psoriasis.

Ixekizumab Linked to Low Risk of Major Cardiovascular Events in Psoriatic Patients - Vimarsana News

Ixekizumab Linked to Low Risk of Major Cardiovascular Events in Psoriatic Patients

An analysis of patients with psoriasis, PsA, or axSpA show risk of MACE with ixekizumab is consistently low.

Safety of Brodalumab for Plaque Psoriasis Treatment - Vimarsana News

Safety of Brodalumab for Plaque Psoriasis Treatment

In research presented at the 2023 SDPA summer conference, new pharmacovigilance data over a 4-year span aligned with the established safety profile on brodalumab.